The Cost of Cancer Medication

February 24th, 2015 by Sara Mears

Why are cancer drug prices skyrocketing? What can be done to rein in costs when drug companies are a “corporate monopoly” with the highest profits of any industry? The patient power of grass-roots groups such as ACKC may hold the solution, says Hagop Kantarjian, M.D., a leader in the in the fight to lower drug costs. Full article coming soon…

Read More

Day 41

February 21st, 2015 by Alan the CPA

It’s now February 15, and I have now completed my second full Sutent cycle of two weeks on and one week off. So far the side effects are being well tolerated. I am being hit with occasional bouts of nausea, which has just been nausea and thankfully, nothing else. These bouts come and go without warning and last just a few minutes, the worst being when they wake me at night. I have been carrying… More →

Read More

Exposome

February 16th, 2015 by Jay Bitkower

A recent segment on NPR, segment, reported about a study, involving tens of thousands of participants over a 50-year period, by Dr. Barbara Cohn from UC Berkeley looking into the effect of environmental factors on the development of breast cancer in mothers and their children. Dr. Cohn plans to map out what’s called the “exposome” (see exposome), which is a map of the exposure of an individual over his or her lifetime to various environmental and… More →

Read More

Day 28

February 2nd, 2015 by Alan the CPA

It’s now February 2nd, and I’m now on my fourth week of Sutent, and in light of my previous prescription problems, I called CureAScript for a refill, this was another adventure, as the phone call to refill the prescription took thirty-three minutes. Saw my oncologist on Friday, my blood labs are fine, especially kidney and liver functions and red blood cell counts. I find the Sutent side effects to be quite tolerable, the only effects… More →

Read More

Day 23

January 28th, 2015 by Alan the CPA

This past Monday, January 26th, I started my second 2-week course of Sutent. So far side effects have been very tolerable and nothing I can’t live with. Only thing bothering me right now is very slight nausea, some itching, acne eruptions on face, neck and chest, some loss of taste. I had blood drawn the other day and have an appointment with my cancer doc on Friday.

Read More

Day 14

January 19th, 2015 by Alan the CPA

Completed first 14-day course of Sutent. So far vary tolerable. Now have a week off. Side effects: nausea which has responded well to Zofran, some lost of taste, skin is getting dry and a little blotchy especially after showering. Blood pressure has been constant, and I have lost 3 pounds.

Read More

Day 5

January 10th, 2015 by Alan the CPA

As of today, January 10, 2015, the only adverse reactions I’ve had to Sutent are some fatigue and just a twinge of nausea.

Read More

Challenges Filling the Prescription

January 10th, 2015 by Alan the CPA

Upon return from France in September, I changed oncologists, with my new oncologist placing a prescription for Sutent, on October 27, 2014, at a local pharmacy with whom he had previously worked. The pharmacy called me a week later stating that Pfizer was out-of-stock, and they again called me the following day to say that under the direction of my insurance carrier the prescription would need to be transferred to a “Specialty Pharmacy.” I spoke… More →

Read More

Background

January 10th, 2015 by Alan the CPA

I was originally diagnosed with kidney cancer during September, 2000. My first symptom was blood in my urine. Tests revealed a tumor on my left kidney, which was pressing into my spleen and lesions within both lungs. I had surgery to remove the kidney and spleen, and, in 2001, I followed up with high-dose IL-2. The lung lesions responded quickly and completely to the therapy, and I was declared cancer free during the fourth quarter… More →

Read More

Rebound and Resistance in Targeted Therapies

December 24th, 2014 by Bryan Lewis

John Ebos of Roswell Park Cancer Institute was granted a Career Development Award by the Congressionally Directed Medical Research Programs of the Department of Defense (DoD) to study, using a pre-clinical model, rebound and resistance to targeted therapies in RCC. This two-year grant was funded at $602,996 in Fiscal Year 2013 (the latest award year). This project is designed to answer a number of important questions, in regard to targeted therapy, that have not been… More →

Read More